Last updated

Other namesLeukaemia
Acute leukemia-ALL.jpg
A Wright's stained bone marrow aspirate smear from a person with B-cell acute lymphoblastic leukemia.
Specialty Hematology and oncology
Symptoms Bleeding, bruising, fatigue, fever, increased risk of infections [2]
Usual onsetAll ages, [3] most common in 60s and 70s. [4] It is the most common malignant cancer in children, but the cure rates are also higher for them.
Causes Inherited and environmental factors [5]
Risk factors Smoking, family history, ionizing radiation, some chemicals, prior chemotherapy, Down syndrome. [3] [5]
Diagnostic method Blood tests, bone marrow biopsy [2]
Treatment Chemotherapy, radiation therapy, targeted therapy, bone marrow transplant, supportive care [3] [6]
Prognosis Five-year survival rate 57% (U.S.) [4]
Frequency2.3 million (2015) [7]
Deaths353,500 (2015) [8]

Leukemia (also spelled leukaemia and pronounced /lˈkmə/ [1] loo-KEE-mee-ə) is a group of blood cancers that usually begin in the bone marrow and result in high numbers of abnormal blood cells. [9] These blood cells are not fully developed and are called blasts or leukemia cells. [2] Symptoms may include bleeding and bruising, bone pain, fatigue, fever, and an increased risk of infections. [2] These symptoms occur due to a lack of normal blood cells. [2] Diagnosis is typically made by blood tests or bone marrow biopsy. [2]


The exact cause of leukemia is unknown. [5] A combination of genetic factors and environmental (non-inherited) factors are believed to play a role. [5] Risk factors include smoking, ionizing radiation, petrochemicals (such as benzene), prior chemotherapy, and Down syndrome. [5] [3] People with a family history of leukemia are also at higher risk. [3] There are four main types of leukemia—acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML)—as well as a number of less common types. [3] [10] Leukemias and lymphomas both belong to a broader group of tumors that affect the blood, bone marrow, and lymphoid system, known as tumors of the hematopoietic and lymphoid tissues. [11] [12]

Treatment may involve some combination of chemotherapy, radiation therapy, targeted therapy, and bone marrow transplant, in addition to supportive care and palliative care as needed. [3] [6] Certain types of leukemia may be managed with watchful waiting. [3] The success of treatment depends on the type of leukemia and the age of the person. Outcomes have improved in the developed world. [10] Five-year survival rate is 65% in the United States. [4] In children under 15 in first-world countries, the five-year survival rate is greater than 60% or even 90%, depending on the type of leukemia. [13] In children with acute leukemia who are cancer-free after five years, the cancer is unlikely to return. [13]

In 2015, leukemia was present in 2.3 million people worldwide and caused 353,500 deaths. [7] [8] In 2012 it newly developed in 352,000 people. [10] It is the most common type of cancer in children, with three-quarters of leukemia cases in children being the acute lymphoblastic type. [3] However, over 90% of all leukemias are diagnosed in adults, with CLL and AML being most common in adults. [3] [14] It occurs more commonly in the developed world. [10]


Four major kinds of leukemia
Cell typeAcuteChronic
Lymphocytic leukemia
(or "lymphoblastic")
Acute lymphoblastic leukemia
Chronic lymphocytic leukemia
Myelogenous leukemia
("myeloid" or "nonlymphocytic")
Acute myelogenous leukemia
(AML or myeloblastic)
Chronic myelogenous leukemia
An explanation of acute leukemia

General classification

Clinically and pathologically, leukemia is subdivided into a variety of large groups. The first division is between its acute and chronic forms: [15]

Additionally, the diseases are subdivided according to which kind of blood cell is affected. This divides leukemias into lymphoblastic or lymphocytic leukemias and myeloid or myelogenous leukemias : [15]

Combining these two classifications provides a total of four main categories. Within each of these main categories, there are typically several subcategories. Finally, some rarer types are usually considered to be outside of this classification scheme. [15] [16]

Specific types


Signs and symptoms

Common symptoms of chronic or acute leukemia Symptoms of leukemia.png
Common symptoms of chronic or acute leukemia

The most common symptoms in children are easy bruising, pale skin, fever, and an enlarged spleen or liver. [34]

Damage to the bone marrow, by way of displacing the normal bone marrow cells with higher numbers of immature white blood cells, results in a lack of blood platelets, which are important in the blood clotting process. This means people with leukemia may easily become bruised, bleed excessively, or develop pinprick bleeds (petechiae). [35]

White blood cells, which are involved in fighting pathogens, may be suppressed or dysfunctional. This could cause the person's immune system to be unable to fight off a simple infection or to start attacking other body cells. Because leukemia prevents the immune system from working normally, some people experience frequent infection, ranging from infected tonsils, sores in the mouth, or diarrhea to life-threatening pneumonia or opportunistic infections. [36]

Finally, the red blood cell deficiency leads to anemia, which may cause dyspnea and pallor. [37]

Some people experience other symptoms, such as fevers, chills, night sweats, weakness in the limbs, feeling fatigued and other common flu-like symptoms. Some people experience nausea or a feeling of fullness due to an enlarged liver and spleen; this can result in unintentional weight loss. Blasts affected by the disease may come together and become swollen in the liver or in the lymph nodes causing pain and leading to nausea. [38]

If the leukemic cells invade the central nervous system, then neurological symptoms (notably headaches) can occur. Uncommon neurological symptoms like migraines, seizures, or coma can occur as a result of brain stem pressure. All symptoms associated with leukemia can be attributed to other diseases. Consequently, leukemia is always diagnosed through medical tests.

The word leukemia, which means 'white blood', is derived from the characteristic high white blood cell count that presents in most affected people before treatment. The high number of white blood cells is apparent when a blood sample is viewed under a microscope, with the extra white blood cells frequently being immature or dysfunctional. The excessive number of cells can also interfere with the level of other cells, causing further harmful imbalance in the blood count. [39]

Some people diagnosed with leukemia do not have high white blood cell counts visible during a regular blood count. This less-common condition is called aleukemia. The bone marrow still contains cancerous white blood cells that disrupt the normal production of blood cells, but they remain in the marrow instead of entering the bloodstream, where they would be visible in a blood test. For a person with aleukemia, the white blood cell counts in the bloodstream can be normal or low. Aleukemia can occur in any of the four major types of leukemia, and is particularly common in hairy cell leukemia. [40]


There is no single known cause for any of the different types of leukemias. The few known causes, which are not generally factors within the control of the average person, account for relatively few cases. [41] The cause for most cases of leukemia is unknown. The different leukemias likely have different causes. [42]

Leukemia, like other cancers, results from mutations in the DNA. Certain mutations can trigger leukemia by activating oncogenes or deactivating tumor suppressor genes, and thereby disrupting the regulation of cell death, differentiation or division. These mutations may occur spontaneously or as a result of exposure to radiation or carcinogenic substances. [43]

Among adults, the known causes are natural and artificial ionizing radiation and petrochemicals, notably benzene and alkylating chemotherapy agents for previous malignancies. [44] [45] [46] Use of tobacco is associated with a small increase in the risk of developing acute myeloid leukemia in adults. [44] Cohort and case-control studies have linked exposure to some petrochemicals and hair dyes to the development of some forms of leukemia. Diet has very limited or no effect, although eating more vegetables may confer a small protective benefit. [41]

Viruses have also been linked to some forms of leukemia. For example, human T-lymphotropic virus (HTLV-1) causes adult T-cell leukemia. [47]

A few cases of maternal-fetal transmission (a baby acquires leukemia because its mother had leukemia during the pregnancy) have been reported. [44] Children born to mothers who use fertility drugs to induce ovulation are more than twice as likely to develop leukemia during their childhoods than other children. [48]

In a recent systematic review and meta-analysis of any type of leukemia in neonates using phototherapy, typically to treat neonatal jaundice, a statistically significant association was detected between using phototherapy and myeloid leukemia. However, it is still questionable whether phototherapy is genuinely the cause of cancer or simply a result of the same underlying factors that gave rise to cancer. [49]


Large doses of Sr-90 emission from nuclear reactor accidents, nicknamed bone seeker increases the risk of bone cancer and leukemia in animals and is presumed to do so in people. [50]

Genetic conditions

Some people have a genetic predisposition towards developing leukemia. This predisposition is demonstrated by family histories and twin studies. [44] The affected people may have a single gene or multiple genes in common. In some cases, families tend to develop the same kinds of leukemia as other members; in other families, affected people may develop different forms of leukemia or related blood cancers. [44]

In addition to these genetic issues, people with chromosomal abnormalities or certain other genetic conditions have a greater risk of leukemia. [45] For example, people with Down syndrome have a significantly increased risk of developing forms of acute leukemia (especially acute myeloid leukemia), and Fanconi anemia is a risk factor for developing acute myeloid leukemia. [44] Mutation in SPRED1 gene has been associated with a predisposition to childhood leukemia. [51]

Chronic myelogenous leukemia is associated with a genetic abnormality called the Philadelphia translocation; 95% of people with CML carry the Philadelphia mutation, although this is not exclusive to CML and can be observed in people with other types of leukemia. [52] [53] [54] [55]

Non-ionizing radiation

Whether or not non-ionizing radiation causes leukemia has been studied for several decades. The International Agency for Research on Cancer expert working group undertook a detailed review of all data on static and extremely low frequency electromagnetic energy, which occurs naturally and in association with the generation, transmission, and use of electrical power. [56] They concluded that there is limited evidence that high levels of ELF magnetic (but not electric) fields might cause some cases of childhood leukemia. [56] No evidence for a relationship to leukemia or another form of malignancy in adults has been demonstrated. [56] Since exposure to such levels of ELFs is relatively uncommon, the World Health Organization concludes that ELF exposure, if later proven to be causative, would account for just 100 to 2400 cases worldwide each year, representing 0.2 to 4.9% of the total incidence of childhood leukemia for that year (about 0.03 to 0.9% of all leukemias). [57]


The increase in white blood cells in leukemia. Leukemia- SAG.jpg
The increase in white blood cells in leukemia.

Diagnosis is usually based on repeated complete blood counts and a bone marrow examination following observations of the symptoms. Sometimes, blood tests may not show that a person has leukemia, especially in the early stages of the disease or during remission. A lymph node biopsy can be performed to diagnose certain types of leukemia in certain situations. [58]

Following diagnosis, blood chemistry tests can be used to determine the degree of liver and kidney damage or the effects of chemotherapy on the person. When concerns arise about other damages due to leukemia, doctors may use an X-ray, MRI, or ultrasound. These can potentially show leukemia's effects on such body parts as bones (X-ray), the brain (MRI), or the kidneys, spleen, and liver (ultrasound). CT scans can be used to check lymph nodes in the chest, though this is uncommon. [59]

Despite the use of these methods to diagnose whether or not a person has leukemia, many people have not been diagnosed because many of the symptoms are vague, non-specific, and can refer to other diseases. For this reason, the American Cancer Society estimates that at least one-fifth of the people with leukemia have not yet been diagnosed. [40]


Most forms of leukemia are treated with pharmaceutical medication, typically combined into a multi-drug chemotherapy regimen. Some are also treated with radiation therapy. In some cases, a bone marrow transplant is effective.

Acute lymphoblastic

Management of ALL is directed towards control of bone marrow and systemic (whole-body) disease. Additionally, treatment must prevent leukemic cells from spreading to other sites, particularly the central nervous system (CNS) e.g. monthly lumbar punctures.[ clarification needed ] In general, ALL treatment is divided into several phases:

Chronic lymphocytic

Decision to treat

Hematologists base CLL treatment on both the stage and symptoms of the individual person. A large group of people with CLL have low-grade disease, which does not benefit from treatment. Individuals with CLL-related complications or more advanced disease often benefit from treatment. In general, the indications for treatment are:

Treatment approach

Most CLL cases are incurable by present treatments, so treatment is directed towards suppressing the disease for many years, rather than curing it. The primary chemotherapeutic plan is combination chemotherapy with chlorambucil or cyclophosphamide, plus a corticosteroid such as prednisone or prednisolone. The use of a corticosteroid has the additional benefit of suppressing some related autoimmune diseases, such as immunohemolytic anemia or immune-mediated thrombocytopenia. In resistant cases, single-agent treatments with nucleoside drugs such as fludarabine, [62] pentostatin, or cladribine may be successful. Younger and healthier people may choose allogeneic or autologous bone marrow transplantation in the hope of a permanent cure. [63]

Acute myelogenous

Many different anti-cancer drugs are effective for the treatment of AML. Treatments vary somewhat according to the age of the person and according to the specific subtype of AML. Overall, the strategy is to control bone marrow and systemic (whole-body) disease, while offering specific treatment for the central nervous system (CNS), if involved. [64]

In general, most oncologists rely on combinations of drugs for the initial, induction phase of chemotherapy. Such combination chemotherapy usually offers the benefits of early remission and a lower risk of disease resistance. Consolidation and maintenance treatments are intended to prevent disease recurrence. Consolidation treatment often entails a repetition of induction chemotherapy or the intensification of chemotherapy with additional drugs. By contrast, maintenance treatment involves drug doses that are lower than those administered during the induction phase. [65]

Chronic myelogenous

There are many possible treatments for CML, but the standard of care for newly diagnosed people is imatinib (Gleevec) therapy. [66] Compared to most anti-cancer drugs, it has relatively few side effects and can be taken orally at home. With this drug, more than 90% of people will be able to keep the disease in check for at least five years, [66] so that CML becomes a chronic, manageable condition.

In a more advanced, uncontrolled state, when the person cannot tolerate imatinib, or if the person wishes to attempt a permanent cure, then an allogeneic bone marrow transplantation may be performed. This procedure involves high-dose chemotherapy and radiation followed by infusion of bone marrow from a compatible donor. Approximately 30% of people die from this procedure. [66]

Hairy cell

Decision to treat
People with hairy cell leukemia who are symptom-free typically do not receive immediate treatment. Treatment is generally considered necessary when the person shows signs and symptoms such as low blood cell counts (e.g., infection-fighting neutrophil count below 1.0 K/µL), frequent infections, unexplained bruises, anemia, or fatigue that is significant enough to disrupt the person's everyday life. [67]

Typical treatment approach
People who need treatment usually receive either one week of cladribine, given daily by intravenous infusion or a simple injection under the skin, or six months of pentostatin, given every four weeks by intravenous infusion. In most cases, one round of treatment will produce a prolonged remission. [68]

Other treatments include rituximab infusion or self-injection with Interferon-alpha. In limited cases, the person may benefit from splenectomy (removal of the spleen). These treatments are not typically given as the first treatment because their success rates are lower than cladribine or pentostatin. [69]

T-cell prolymphocytic

Most people with T-cell prolymphocytic leukemia, a rare and aggressive leukemia with a median survival of less than one year, require immediate treatment. [70]

T-cell prolymphocytic leukemia is difficult to treat, and it does not respond to most available chemotherapeutic drugs. [70] Many different treatments have been attempted, with limited success in certain people: purine analogues (pentostatin, fludarabine, cladribine), chlorambucil, and various forms of combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone CHOP, cyclophosphamide, vincristine, prednisone [COP], vincristine, doxorubicin, prednisone, etoposide, cyclophosphamide, bleomycin VAPEC-B). Alemtuzumab (Campath), a monoclonal antibody that attacks white blood cells, has been used in treatment with greater success than previous options. [70]

Some people who successfully respond to treatment also undergo stem cell transplantation to consolidate the response. [70]

Juvenile myelomonocytic

Treatment for juvenile myelomonocytic leukemia can include splenectomy, chemotherapy, and bone marrow transplantation. [71]


The success of treatment depends on the type of leukemia and the age of the person. Outcomes have improved in the developed world. [10] The average five-year survival rate is 65% in the United States. [4] In children under 15, the five-year survival rate is greater (60 to 85%), depending on the type of leukemia. [13] In children with acute leukemia who are cancer-free after five years, the cancer is unlikely to return. [13]

Outcomes depend on whether it is acute or chronic, the specific abnormal white blood cell type, the presence and severity of anemia or thrombocytopenia, the degree of tissue abnormality, the presence of metastasis and lymph node and bone marrow infiltration, the availability of therapies and the skills of the health care team. Treatment outcomes may be better when people are treated at larger centers with greater experience. [72]


Deaths due to leukemia per million persons in 2012
.mw-parser-output .refbegin{font-size:90%;margin-bottom:0.5em}.mw-parser-output .refbegin-hanging-indents>ul{margin-left:0}.mw-parser-output .refbegin-hanging-indents>ul>li{margin-left:0;padding-left:3.2em;text-indent:-3.2em}.mw-parser-output .refbegin-hanging-indents ul,.mw-parser-output .refbegin-hanging-indents ul li{list-style:none}@media(max-width:720px){.mw-parser-output .refbegin-hanging-indents>ul>li{padding-left:1.6em;text-indent:-1.6em}}.mw-parser-output .refbegin-columns{margin-top:0.3em}.mw-parser-output .refbegin-columns ul{margin-top:0}.mw-parser-output .refbegin-columns li{page-break-inside:avoid;break-inside:avoid-column}
.mw-parser-output .legend{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .legend-color{display:inline-block;min-width:1.25em;height:1.25em;line-height:1.25;margin:1px 0;text-align:center;border:1px solid black;background-color:transparent;color:black}.mw-parser-output .legend-text{}
86-132 Leukaemia world map-Deaths per million persons-WHO2012.svg
Deaths due to leukemia per million persons in 2012

In 2010, globally, approximately 281,500 people died of leukemia. [73] In 2000, approximately 256,000 children and adults around the world developed a form of leukemia, and 209,000 died from it. [74] This represents about 3% of the almost seven million deaths due to cancer that year, and about 0.35% of all deaths from any cause. [74] Of the sixteen separate sites the body compared, leukemia was the 12th most common class of neoplastic disease and the 11th most common cause of cancer-related death. [74] Leukemia occurs more commonly in the developed world. [75]

United States

About 245,000 people in the United States are affected with some form of leukemia, including those that have achieved remission or cure. Rates from 1975 to 2011 have increased by 0.7% per year among children. [76] Approximately 44,270 new cases of leukemia were diagnosed in the year 2008 in the US. [77] This represents 2.9% of all cancers (excluding simple basal cell and squamous cell skin cancers) in the United States, and 30.4% of all blood cancers. [78]

Among children with some form of cancer, about a third have a type of leukemia, most commonly acute lymphoblastic leukemia. [77] A type of leukemia is the second most common form of cancer in infants (under the age of 12 months) and the most common form of cancer in older children. [79] Boys are somewhat more likely to develop leukemia than girls, and white American children are almost twice as likely to develop leukemia than black American children. [79] Only about 3% cancer diagnoses among adults are for leukemias, but because cancer is much more common among adults, more than 90% of all leukemias are diagnosed in adults. [77]

Race is a risk factor in the United States. Hispanics, especially those under the age of 20, are at the highest risk for leukemia, while whites, Native Americans, Asian Americans, and Alaska Natives are at higher risk than African Americans. [80]

More men than women are diagnosed with leukemia and die from the disease. Around 30 percent more men than women have leukemia. [81]


In Australia, leukemia is the eleventh most common cancer. [82] In 2014–2018, Australians diagnosed with leukaemia had a 64% chance (65% for males and 64% for females) of surviving for five years compared to the rest of the Australian populationthere was a 21% increase in survival rates between 19891993. [82]


Overall, leukemia is the eleventh most common cancer in the UK (around 8,600 people were diagnosed with the disease in 2011), and it is the ninth most common cause of cancer death (around 4,800 people died in 2012). [83]


Rudolf Virchow Rudolf Virchow.jpg
Rudolf Virchow

Leukemia was first described by anatomist and surgeon Alfred-Armand-Louis-Marie Velpeau in 1827. A more complete description was given by pathologist Rudolf Virchow in 1845. Around ten years after Virchow's findings, pathologist Franz Ernst Christian Neumann found that the bone marrow of a deceased person with leukemia was colored "dirty green-yellow" as opposed to the normal red. This finding allowed Neumann to conclude that a bone marrow problem was responsible for the abnormal blood of people with leukemia. [84]

By 1900, leukemia was viewed as a family of diseases as opposed to a single disease. By 1947, Boston pathologist Sidney Farber believed from past experiments that aminopterin, a folic acid mimic, could potentially cure leukemia in children. The majority of the children with ALL who were tested showed signs of improvement in their bone marrow, but none of them were actually cured. Nevertheless, this result did lead to further experiments. [85]

In 1962, researchers Emil J. Freireich, Jr. and Emil Frei III used combination chemotherapy to attempt to cure leukemia. The tests were successful with some people surviving long after the tests. [86]


Observing an abnormally large number of white blood cells in a blood sample from a person, Virchow called the condition Leukämie in German, which he formed from the two Greek words leukos (λευκός), meaning 'white', and haima (αἷμα), meaning 'blood'. [87] It was formerly also called leucemia. [88]

Society and culture

According to Susan Sontag, leukemia was often romanticized in 20th-century fiction, portrayed as a joy-ending, clean disease whose fair, innocent and gentle victims die young or at the wrong time. As such, it was the cultural successor to tuberculosis, which held this cultural position until it was discovered to be an infectious disease. [89] The 1970 romance novel Love Story is an example of this romanticization of leukemia. [90]

In the United States, around $5.4 billion is spent on treatment a year. [91]

Research directions

Significant research into the causes, prevalence, diagnosis, treatment, and prognosis of leukemia is being performed. Hundreds of clinical trials are being planned or conducted at any given time. [92] Studies may focus on effective means of treatment, better ways of treating the disease, improving the quality of life for people, or appropriate care in remission or after cures. [93]

In general, there are two types of leukemia research: clinical or translational research and basic research. Clinical/translational research focuses on studying the disease in a defined and generally immediately applicable way, such as testing a new drug in people. By contrast, basic science research studies the disease process at a distance, such as seeing whether a suspected carcinogen can cause leukemic changes in isolated cells in the laboratory or how the DNA changes inside leukemia cells as the disease progresses. The results from basic research studies are generally less immediately useful to people with the disease. [94]

Treatment through gene therapy is currently being pursued. One such approach used genetically modified T cells, known as chimeric antigen receptor T cells (CAR-T cells), to attack cancer cells. In 2011, a year after treatment, two of the three people with advanced chronic lymphocytic leukemia were reported to be cancer-free [95] and in 2013, three of five subjects who had acute lymphocytic leukemia were reported to be in remission for five months to two years. [96] Subsequent studies with a variety of CAR-T types continue to be promising. [97] As of 2018, two CAR-T therapies have been approved by the Food and Drug Administration. CAR-T treatment has significant side effects, [98] and loss of the antigen targeted by the CAR-T cells is a common mechanism for relapse. [97] The stem cells that cause different types of leukemia are also being researched. [99]


Leukemia is rarely associated with pregnancy, affecting only about 1 in 10,000 pregnant women. [100] How it is handled depends primarily on the type of leukemia. Nearly all leukemias appearing in pregnant women are acute leukemias. [101] Acute leukemias normally require prompt, aggressive treatment, despite significant risks of pregnancy loss and birth defects, especially if chemotherapy is given during the developmentally sensitive first trimester. [100] Chronic myelogenous leukemia can be treated with relative safety at any time during pregnancy with Interferon-alpha hormones. [100] Treatment for chronic lymphocytic leukemias, which are rare in pregnant women, can often be postponed until after the end of the pregnancy. [100] [101]

See also

Related Research Articles

<span class="mw-page-title-main">Lymphoma</span> Hematologic cancer that affects lymphocytes

Lymphoma is a group of blood and lymph tumors that develop from lymphocytes. The name usually refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night.

<span class="mw-page-title-main">Myelodysplastic syndrome</span> Diverse collection of blood-related cancers

A myelodysplastic syndrome (MDS) is one of a group of cancers in which immature blood cells in the bone marrow do not mature, and as a result, do not develop into healthy blood cells. Early on, no symptoms typically are seen. Later, symptoms may include feeling tired, shortness of breath, bleeding disorders, anemia, or frequent infections. Some types may develop into acute myeloid leukemia.

<span class="mw-page-title-main">Chronic lymphocytic leukemia</span> Medical condition

Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes. Early on, there are typically no symptoms. Later, non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason may occur. Enlargement of the spleen and low red blood cells (anemia) may also occur. It typically worsens gradually over years.

<span class="mw-page-title-main">Chronic myelogenous leukemia</span> Medical condition

Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which a proliferation of mature granulocytes and their precursors is found. It is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation called the Philadelphia chromosome.

<span class="mw-page-title-main">Tumors of the hematopoietic and lymphoid tissues</span> Medical condition

Tumors of the hematopoietic and lymphoid tissues or tumours of the haematopoietic and lymphoid tissues are tumors that affect the blood, bone marrow, lymph, and lymphatic system. Because these tissues are all intimately connected through both the circulatory system and the immune system, a disease affecting one will often affect the others as well, making aplasia, myeloproliferation and lymphoproliferation closely related and often overlapping problems. While uncommon in solid tumors, chromosomal translocations are a common cause of these diseases. This commonly leads to a different approach in diagnosis and treatment of hematological malignancies. Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology. In some centers "hematology/oncology" is a single subspecialty of internal medicine while in others they are considered separate divisions. Not all hematological disorders are malignant ("cancerous"); these other blood conditions may also be managed by a hematologist.

<span class="mw-page-title-main">Acute lymphoblastic leukemia</span> Blood cancer characterised by overproduction of lymphoblasts

Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. Symptoms may include feeling tired, pale skin color, fever, easy bleeding or bruising, enlarged lymph nodes, or bone pain. As an acute leukemia, ALL progresses rapidly and is typically fatal within weeks or months if left untreated.

<span class="mw-page-title-main">Myeloproliferative neoplasm</span> Medical condition

Myeloproliferative neoplasms (MPNs) are a group of rare blood cancers in which excess red blood cells, white blood cells or platelets are produced in the bone marrow. Myelo refers to the bone marrow, proliferative describes the rapid growth of blood cells and neoplasm describes that growth as abnormal and uncontrolled.

Lymphoid leukemias are a group of leukemias affecting circulating lymphocytes, a type of white blood cell. The lymphocytic leukemias are closely related to lymphomas of the lymphocytes, to the point that some of them are unitary disease entities that can be called by either name. Such diseases are all lymphoproliferative disorders. Most lymphoid leukemias involve a particular subtype of lymphocytes, the B cells.

<span class="mw-page-title-main">Acute myeloid leukemia</span> Cancer of the myeloid line of blood cells

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally, spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly, and is typically fatal within weeks or months if left untreated.

<span class="mw-page-title-main">Dasatinib</span> Chemical compound

Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by mouth.

<span class="mw-page-title-main">Chronic myelomonocytic leukemia</span> Medical condition

Chronic myelomonocytic leukemia (CMML) is a type of leukemia, which are cancers of the blood-forming cells of the bone marrow. In adults, blood cells are formed in the bone marrow, by a process that is known as haematopoiesis. In CMML, there are increased numbers of monocytes and immature blood cells (blasts) in the peripheral blood and bone marrow, as well as abnormal looking cells (dysplasia) in at least one type of blood cell.

Juvenile myelomonocytic leukemia (JMML) is a rare form of chronic leukemia that affects children, commonly those aged four and younger. The name JMML now encompasses all diagnoses formerly referred to as juvenile chronic myeloid leukemia (JCML), chronic myelomonocytic leukemia of infancy, and infantile monosomy 7 syndrome. The average age of patients at diagnosis is two (2) years old. The World Health Organization has included JMML as a subcategory of myelodysplastic and myeloproliferative disorders.

Minimal residual disease (MRD) is the name given to small numbers of leukaemic cells that remain in the person during treatment, or after treatment when the patient is in remission. It is the major cause of relapse in cancer and leukemia. Up until a decade ago, none of the tests used to assess or detect cancer were sensitive enough to detect MRD. Now, however, very sensitive molecular biology tests are available, based on DNA, RNA or proteins. These can measure minute levels of cancer cells in tissue samples, sometimes as low as one cancer cell in a million normal cells.

Acute myelomonocytic leukemia (AMML) is a form of acute myeloid leukemia that involves a proliferation of CFU-GM myeloblasts and monoblasts. AMML occurs with a rapid increase amount in white blood cell count and is defined by more than 20% of myeloblast in the bone marrow. It is classified under "M4" in the French-American-British classification (FAB). It is classified under "AML, not otherwise classified" in the WHO classification.

Biphenotypic acute leukaemia (BAL) is an uncommon type of leukemia which arises in multipotent progenitor cells which have the ability to differentiate into both myeloid and lymphoid lineages. It is a subtype of "leukemia of ambiguous lineage".

Leukostasis is a medical emergency most commonly seen in patients with acute myeloid leukemia. It is characterized by an extremely elevated blast cell count and symptoms of decreased tissue perfusion. The pathophysiology of leukostasis is not well understood, but inadequate delivery of oxygen to the body's cells is the result. Leukostasis is diagnosed when white cell plugs are seen in the microvasculature. The most common symptoms are dyspnea and hypoxia, usually accompanied by visual changes, headaches, dizziness, confusion, somnolence, and coma. Prompt treatment is required since, if left untreated, it has a very high mortality rate. Treatments aim to rapidly reduce white blood cell counts while also treating the underlying disorder.

<span class="mw-page-title-main">Childhood leukemia</span> Medical condition

Childhood leukemia is leukemia that occurs in a child and is a type of childhood cancer. Childhood leukemia is the most common childhood cancer, accounting for 29% of cancers in children aged 0–14 in 2018. There are multiple forms of leukemia that occur in children, the most common being acute lymphoblastic leukemia (ALL) followed by acute myeloid leukemia (AML). Survival rates vary depending on the type of leukemia, but may be as high as 90% in ALL.

<span class="mw-page-title-main">Venetoclax</span> Medication

Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).

Clonal hypereosinophilia, also termed primary hypereosinophilia or clonal eosinophilia, is a grouping of hematological disorders all of which are characterized by the development and growth of a pre-malignant or malignant population of eosinophils, a type of white blood cell that occupies the bone marrow, blood, and other tissues. This population consists of a clone of eosinophils, i.e. a group of genetically identical eosinophils derived from a sufficiently mutated ancestor cell.

<span class="mw-page-title-main">T-cell acute lymphoblastic leukemia</span> Type of acute lymphoblastic leukemia

T-cell acute lymphoblastic leukemia (T-ALL) is a type of acute lymphoblastic leukemia with aggressive malignant neoplasm of the bone marrow. Acute lymphoblastic leukemia (ALL) is a condition where immature white blood cells accumulate in the bone marrow, subsequently crowding out normal white blood cells and create build-up in the liver, spleen, and lymph nodes. The two most common types of ALL are B-lymphocytes and T-lymphocytes, where the first protects the body against viruses and bacteria through antibody production which can directly destroy target cells or trigger others to do so, whilst the latter directly destroy bacteria or cells infected with viruses. Approximately 20% of all ALL patients are categorized specifically to suffer from T-ALL and it is seen to be more prevalent in the adult population in comparison to children, with incidences shown to diminish with age. Amongst T-ALL cases in the pediatric population, a median onset of age 9 has been identified and the disease is particularly prominent amongst adolescents. The disease stems from cytogenic and molecular abnormalities, resulting in disruption of developmental pathways controlling thymocyte development, tumor suppressor development, and alterations in control of cell growth and proliferation. Distinct from adult T-cell leukemia where T-cell lymphotropic virus Type I causes malignant maturation of T-cells, T-ALL is a precursor for lymphoid neoplasm. Its clinical presentation most commonly includes infiltration of the central nervous system (CNS), and further identifies mediastinal mass presence originating from the thymus, along with extramedullary involvement of multiple organs including the lymph node as a result of hyperleukocytosis.


  1. 1 2 "Leukemia". Merriam-Webster.
  2. 1 2 3 4 5 6 "What You lNeed To Know About™ Leukemia". National Cancer Institute. 23 December 2013. Archived from the original on 6 July 2014. Retrieved 18 June 2014.
  3. 1 2 3 4 5 6 7 8 9 10 "A Snapshot of Leukemia". NCI. Archived from the original on 4 July 2014. Retrieved 18 June 2014.
  4. 1 2 3 4 "SEER Stat Fact Sheets: Leukemia". National Cancer Institute. 2011. Archived from the original on 16 July 2016.
  5. 1 2 3 4 5 Hutter JJ (June 2010). "Childhood leukemia". Pediatrics in Review. 31 (6): 234–241. doi:10.1542/pir.31-6-234. PMID   20516235.
  6. 1 2 Cordo' V, van der Zwet JC, Canté-Barrett K, Pieters R, Meijerink JP (January 2021). "T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies". Blood Cancer Discovery. 2 (1): 19–31. doi: 10.1158/2643-3230.BCD-20-0093 . PMC   8447273 . PMID   34661151.
  7. 1 2 Vos, Theo; et al. (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC   5055577 . PMID   27733282.
  8. 1 2 Wang, Haidong; et al. (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC   5388903 . PMID   27733281.
  9. "Leukemia". NCI. 1 January 1980. Archived from the original on 27 May 2014. Retrieved 13 June 2014. Cancer that starts in blood-forming tissue, such as the bone marrow, and causes large numbers of abnormal blood cells
  10. 1 2 3 4 5 World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.13. ISBN   978-9283204299.
  11. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. (July 2009). "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes". Blood. 114 (5): 937–951. doi: 10.1182/blood-2009-03-209262 . PMID   19357394. S2CID   3101472.
  12. Baba AI, Câtoi C, eds. (2007). Comparative oncology. Bucharest: The Publishing House of the Romanian Academy. p. Chapter 17. ISBN   978-973-27-1457-7. Archived from the original on 10 September 2017.
  13. 1 2 3 4 American Cancer Society (2 March 2014). "Survival rates for childhood leukemia". Archived from the original on 14 July 2014.
  14. "Chronic Lymphocytic Leukemia (CLL) - Hematology and Oncology". MSD Manual Professional Edition. Retrieved 1 February 2020.
  15. 1 2 3 "Questions and Answers About Leukemia" (PDF). Centers for Disease Control and Prevention . Archived (PDF) from the original on 30 July 2021. Retrieved 8 August 2021.
  16. "Leukemia - Symptoms and causes". Mayo Clinic. Retrieved 8 August 2021.
  17. "Key Statistics for Acute Lymphocytic Leukemia (ALL)". American Cancer Society. 8 January 2019. Retrieved 9 December 2019.
  18. "Finding Cancer Statistics » Cancer Stat Fact Sheets »Chronic Lymphocytic Leukemia". National Cancer Institute. Archived from the original on 16 April 2008.
  19. "Survival: Acute Myeloid Leukaemia". Cancer Research UK. 10 July 2019. Retrieved 2 December 2019.
  20. "Novartis Oncology". Archived from the original on 5 November 2013.
  21. Moyer P (12 June 2006). "Patients with Chronic Myelogenous Leukemia Continue to Do Well on Imatinib at 5-Year Follow-Up". Medscape Medical News. Archived from the original on 15 May 2013.
  22. "Updated Results of Tyrosine Kinase Inhibitors in CML". ASCO 2006 Conference Summaries. Archived from the original on 29 December 2007.
  23. Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, et al. (December 2005). "Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years". Cancer. 104 (11): 2442–2448. doi: 10.1002/cncr.21447 . PMID   16245328. S2CID   43282431.
  24. Matutes E (January 1998). "T-cell Prolymphocytic Leukemia". Cancer Control. 5 (1): 19–24. doi: 10.1177/107327489800500102 . PMID   10761013. Archived from the original on 11 February 2009.
  25. Valbuena JR, Herling M, Admirand JH, Padula A, Jones D, Medeiros LJ (March 2005). "T-cell prolymphocytic leukemia involving extramedullary sites". American Journal of Clinical Pathology. 123 (3): 456–464. doi: 10.1309/93P4-2RNG-5XBG-3KBE . PMID   15716243. Archived from the original on 15 May 2013.
  26. Jaffe ES, Harris NL, Stein H, Vardiman JW, et al. (World Health Organization, International Agency for Research on Cancer) (2001). Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumors. Vol. 3. Lyon: IARC Press. ISBN   978-92-832-2411-2.
  27. 1 2 Reiter A, Gotlib J (February 2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704–714. doi: 10.1182/blood-2016-10-695973 . PMID   28028030.
  28. Gotlib J (November 2015). "World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management". American Journal of Hematology. 90 (11): 1077–1089. doi:10.1002/ajh.24196. PMID   26486351. S2CID   42668440.
  29. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. (May 2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi: 10.1182/blood-2016-03-643544 . PMID   27069254. S2CID   18338178.
  30. Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I (October 2016). "Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update". Current Hematologic Malignancy Reports. 11 (5): 333–341. doi:10.1007/s11899-016-0338-x. PMC   5031718 . PMID   27510823.
  31. Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103–2110. doi:10.1182/blood-2016-09-687889. PMC   5391620 . PMID   28179280.
  32. Seewald L, Taub JW, Maloney KW, McCabe ER (September 2012). "Acute leukemias in children with Down syndrome". Molecular Genetics and Metabolism. 107 (1–2): 25–30. doi:10.1016/j.ymgme.2012.07.011. PMID   22867885.
  33. Reference list is found at image description page in Wikimedia Commons
  34. Clarke RT, Van den Bruel A, Bankhead C, Mitchell CD, Phillips B, Thompson MJ (October 2016). "Clinical presentation of childhood leukaemia: a systematic review and meta-analysis". Archives of Disease in Childhood. 101 (10): 894–901. doi: 10.1136/archdischild-2016-311251 . PMID   27647842.
  35. Jyothi KT, Subrahmanyam PS, Sravanthi AC (July 2017). "Application of Differential Equations in Medical Science". Research Journal of Science and Technology. 9 (3): 425–426. doi:10.5958/2349-2988.2017.00074.2.
  36. "Types of Leukemia: Common, Rare and More Varieties". Cancer Treatment Centers of America. 5 October 2018. Retrieved 8 October 2021.
  37. "Iron deficiency anemia - Symptoms and causes". Mayo Clinic. Retrieved 5 March 2022.
  38. "Leukemia". Columbia Electronic Encyclopedia, 6th Edition. Retrieved 4 November 2011.
  39. "Leukemia: Symptoms, Signs, Causes, Types & Treatment". Cleveland Clinic. Retrieved 13 October 2022.
  40. 1 2 American Cancer Society (2010). "How is Leukemia Diagnosed?". Detailed Guide: Leukemia – Adult Chronic. American Cancer Society. Archived from the original on 5 April 2010. Retrieved 4 May 2010.
  41. 1 2 Ross JA, Kasum CM, Davies SM, Jacobs DR, Folsom AR, Potter JD (August 2002). "Diet and risk of leukemia in the Iowa Women's Health Study". Cancer Epidemiology, Biomarkers & Prevention. 11 (8): 777–781. PMID   12163333. Archived from the original on 10 September 2017.
  42. Novak EM, Rego EM, eds. (2012). Physiopathogenesis of Hematological Cancer. Bentham Science Publishers. ISBN   978-1-60805-259-2.
  43. Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT, et al. (February 2016). "Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation". Leukemia. 30 (2): 285–294. doi:10.1038/leu.2015.258. PMID   26460209. S2CID   22100511.
  44. 1 2 3 4 5 6 Wiernik PH (2001). Adult leukemias. New York: B. C. Decker. pp. 3–15. ISBN   978-1-55009-111-3.
  45. 1 2 Robinette MS, Cotter S, Van de Water D (2001). Quick Look Series in Veterinary Medicine: Hematology. Teton NewMedia. p. 105. ISBN   978-1-893441-36-1.
  46. Stass SA, Schumacher HR, Rock WR (2000). Handbook of hematologic pathology . New York, N.Y: Marcel Dekker. pp.  193–194. ISBN   978-0-8247-0170-3.
  47. Leonard B (1998). Leukemia: A Research Report. DIANE Publishing. p.  7. ISBN   978-0-7881-7189-5.
  48. Rudant J, Amigou A, Orsi L, Althaus T, Leverger G, Baruchel A, et al. (February 2013). "Fertility treatments, congenital malformations, fetal loss, and childhood acute leukemia: the ESCALE study (SFCE)". Pediatric Blood & Cancer. 60 (2): 301–308. doi:10.1002/pbc.24192. PMID   22610722. S2CID   26010916.
  49. Abdellatif, Mohammed, et al. "Association between neonatal phototherapy and future cancer: an updated systematic review and meta-analysis." European Journal of Pediatrics (2022): 1-13.
  50. "Backgrounder on Radiation Protection and the "Tooth Fairy" Issue". U.S. Nuclear Regulatory Commission. December 2004. Archived from the original on 20 July 2017.
  51. Pasmant E, Ballerini P, Lapillonne H, Perot C, Vidaud D, Leverger G, Landman-Parker J (July 2009). "SPRED1 disorder and predisposition to leukemia in children". Blood. 114 (5): 1131. doi: 10.1182/blood-2009-04-218503 . PMID   19643996.
  52. Salesse S, Verfaillie CM (December 2002). "BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia". Oncogene. 21 (56): 8547–8559. doi: 10.1038/sj.onc.1206082 . PMID   12476301.
  53. "NCI Dictionary of Cancer Terms". National Cancer Institute. 2 February 2011. Archived from the original on 16 February 2017. Retrieved 15 February 2017.
  54. "Do We Know What Causes Chronic Myeloid Leukemia?". www.cancer.org. Archived from the original on 16 February 2017. Retrieved 15 February 2017.
  55. "What is chronic myeloid leukaemia? (CML) – Understanding – Macmillan Cancer Support". www.macmillan.org.uk. Archived from the original on 16 February 2017. Retrieved 15 February 2017.
  56. 1 2 3 Non-Ionizing Radiation, Part 1: Static and Extremely Low-Frequency (ELF) Electric and Magnetic Fields (IARC Monographs on the Evaluation of the Carcinogenic Risks). Geneva: World Health Organisation. 2002. pp. 332–333, 338. ISBN   978-92-832-1280-5. Archived from the original on 6 December 2008.
  57. "WHO | Electromagnetic fields and public health". Archived from the original on 16 February 2009. Retrieved 18 February 2009.
  58. "Diagnosing Chronic Lymphocytic Leukemia in Adults". NYU Langone Health. Archived from the original on 26 March 2021. Retrieved 26 March 2021.
  59. "Chronic Lymphocytic Leukemia (CLL): Tests After Diagnosis". University of Rochester Medical Center. Archived from the original on 26 March 2021. Retrieved 26 March 2021.
  60. Hoffbrand AV, Moss PA, Pettit JE (2006). Essential haematology (5th ed.). Malden, Mass.: Blackwell Pub. ISBN   978-1-4051-3649-5.
  61. National Cancer Institute (1 January 1980). "Chronic Lymphocytic Leukemia (PDQ) Treatment: Stage Information". Archived from the original on 17 October 2007. Retrieved 4 September 2007.
  62. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. (February 2006). "Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia". Blood. 107 (3): 885–891. doi: 10.1182/blood-2005-06-2395 . PMID   16219797.
  63. Gribben JG (January 2009). "Stem cell transplantation in chronic lymphocytic leukemia". Biology of Blood and Marrow Transplantation. 15 (1 Suppl): 53–58. doi:10.1016/j.bbmt.2008.10.022. PMC   2668540 . PMID   19147079.
  64. Baig MQ (22 March 2017). Practical Radiotherapy & Chemotherapy Planning. JP Medical Ltd. ISBN   978-93-86150-01-1.
  65. American Cancer Society (22 March 2012). "Typical treatment of acute myeloid leukemia (except promyelocytic M3)". Detailed Guide: Leukemia – Acute Myeloid (AML). American Cancer Society. Archived from the original on 12 November 2012. Retrieved 31 October 2012.
  66. 1 2 3 Fausel C (October 2007). "Targeted chronic myeloid leukemia therapy: seeking a cure" (PDF). Journal of Managed Care Pharmacy. 13 (8 Suppl A): 8–12. doi:10.18553/jmcp.2007.13.s8-a.8. PMID   17970609. Archived from the original (PDF) on 28 May 2008. Retrieved 18 May 2008.
  67. "Hairy Cell Leukemia". The Lecturio Medical Concept Library. Retrieved 24 July 2021.
  68. Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J, et al. (May 2007). "Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial". Blood. 109 (9): 3672–3675. doi: 10.1182/blood-2006-08-042929 . PMID   17209059.
  69. Saven A, Burian C, Adusumalli J, Koziol JA (April 1999). "Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia". Blood. 93 (8): 2471–2477. doi:10.1182/blood.V93.8.2471. PMID   10194424.
  70. 1 2 3 4 Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, et al. (September 2001). "High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H". Blood. 98 (6): 1721–1726. doi: 10.1182/blood.V98.6.1721 . PMID   11535503. S2CID   26664911.
  71. "JMMLfoundation.org". JMMLfoundation.org. Archived from the original on 25 January 2009. Retrieved 29 August 2010.
  72. Stock W (2010). "Adolescents and young adults with acute lymphoblastic leukemia". Hematology. American Society of Hematology. Education Program. 2010: 21–29. doi:10.1182/asheducation-2010.1.21. PMID   21239766. S2CID   9796380.
  73. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. (December 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2095–2128. doi:10.1016/S0140-6736(12)61728-0. hdl: 10536/DRO/DU:30050819 . PMID   23245604. S2CID   1541253.
  74. 1 2 3 Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ (2001). "Cancer incidence, mortality and survival by site for 14 regions of the world" (PDF). Global Programme on Evidence for Health Policy Discussion Paper No. 13. World Health Organization.
  75. World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.13. ISBN   978-9283204299.
  76. Amitay EL, Keinan-Boker L (June 2015). "Breastfeeding and Childhood Leukemia Incidence: A Meta-analysis and Systematic Review". JAMA Pediatrics. 169 (6): e151025. doi: 10.1001/jamapediatrics.2015.1025 . PMID   26030516.
  77. 1 2 3 "Leukemia Facts & Statistics". The Leukemia & Lymphoma Society. Archived from the original on 16 April 2009. Retrieved 2 July 2009.
  78. Horner MJ, Ries LA, Krapcho M, Neyman N, et al. (eds.). "SEER Cancer Statistics Review, 1975–2006". Surveillance Epidemiology and End Results (SEER). Bethesda, MD: National Cancer Institute. Archived from the original on 26 September 2009. Retrieved 3 November 2009. Table 1.4: Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival Rates By Primary Cancer Site, Sex and Time Period
  79. 1 2 Gurney JG, Smith MA, Ross JA (1999). "Leukemia" (PDF). Cancer Incidence and Survival among Children and Adolescents, United States SEER program 1975–1995. Cancer Statistics Branch, National Cancer Institute. Archived from the original (PDF) on 24 December 2010.
  80. "Childhood Blood Cancers". The Leukemia & Lymphoma Society. Archived from the original on 5 September 2012.
  81. "Facts 2012" (PDF). The Leukemia & Lymphoma Society. Archived from the original on 14 October 2012.
  82. 1 2 canceraustralia.gov.au. 2023 https://www.canceraustralia.gov.au/cancer-types/leukaemia/statistics . Retrieved 3 April 2023.{{cite web}}: Missing or empty |title= (help)
  83. "Leukaemia (all subtypes combined) statistics". Cancer Research UK. Archived from the original on 7 October 2014. Retrieved 27 October 2014.
  84. Thomas, Xavier (6 August 2013). "First contributors in the history of leukemia". World Journal of Hematology. 2 (3): 62–70. doi:10.5315/wjh.v2.i3.62.
  85. Ribatti D (May 2012). "Sidney Farber and the treatment of childhood acute lymphoblastic leukemia with a chemotherapeutic agent". Pediatric Hematology and Oncology. 29 (4): 299–302. doi:10.3109/08880018.2012.678969. PMID   22568792. S2CID   31176962.
  86. Patlak M (March 2002). "Targeting leukemia: from bench to bedside". FASEB Journal. 16 (3): 273. doi:10.1096/fj.02-0029bkt. PMID   11874976. S2CID   221751708.
  87. "Leukemia: MedlinePlus Medical Encyclopedia". MedlinePlus. 8 May 2019. Retrieved 16 May 2019.
  88. "leukemia". Online Etymology Dictionary. Retrieved 14 February 2023.
  89. Sontag S (1978). Illness as Metaphor. New York: Farrar, Straus and Giroux. pp.  18. ISBN   978-0-374-17443-9.
  90. Bey B (2017). Cancer as Metaphor: The Metaphorical Implications of Romanticized Illness in Young Adult Fiction (English Honors thesis). Trinity University. p. 5-6.
  91. "A Snapshot of Leukemia". NCI. Archived from the original on 4 July 2014. Retrieved 18 June 2014.
  92. "Search of: leukemia — List Results — ClinicalTrials.gov". Archived from the original on 15 September 2010.
  93. "Learn About Clinical Studies - Reasons for Conducting Clinical Studies". Clinicaltrials.gov. Retrieved 3 March 2023.
  94. "Understanding Clinical Trials for Blood Cancers" (PDF). Leukemia and Lymphoma Society. Archived from the original (PDF) on 5 January 2011. Retrieved 19 May 2010.
  95. Jaslow R. "New Leukemia Therapy Destroys Cancer by Turning Blood Cells into "Assassins"". CBSnews.com HealthPop section. Archived from the original on 31 March 2014. Retrieved 11 August 2011.
  96. Coghlan A (26 March 2013). "Gene therapy cures leukaemia in eight days". The New Scientist. Archived from the original on 15 May 2015. Retrieved 15 April 2013.
  97. 1 2 Zhao J, Song Y, Liu D (February 2019). "Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia". Journal of Hematology & Oncology. 12 (1): 17. doi:10.1186/s13045-019-0705-x. PMC   6376657 . PMID   30764841.
  98. Zheng PP, Kros JM, Li J (June 2018). "Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts". Drug Discovery Today. 23 (6): 1175–1182. doi: 10.1016/j.drudis.2018.02.012 . hdl:1765/105338. PMID   29501911.
  99. "How we're beating leukaemia". Leukaemia & Lymphoma Research. Archived from the original on 27 September 2013. Retrieved 24 September 2013.
  100. 1 2 3 4 Shapira T, Pereg D, Lishner M (September 2008). "How I treat acute and chronic leukemia in pregnancy". Blood Reviews. 22 (5): 247–259. doi:10.1016/j.blre.2008.03.006. PMID   18472198.
  101. 1 2 Koren G, Lishner M (2010). "Pregnancy and commonly used drugs in hematology practice". Hematology. American Society of Hematology. Education Program. 2010: 160–165. doi: 10.1182/asheducation-2010.1.160 . PMID   21239787. S2CID   21832575.